Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394–424.

Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol Nat Publishing Group. 2009;6:87–95.

Article  Google Scholar 

Kiciński M, Vangronsveld J, Nawrot TS. An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-Analysis. PLOS ONE Public Library of Science. 2011;6:e27130.

Article  Google Scholar 

Zeegers MPA, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma. Cancer. 2003;97:1894–903.

Article  Google Scholar 

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.

CAS  Article  Google Scholar 

Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016;315:68.

CAS  Article  Google Scholar 

Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, et al. Androgen Receptor Mutations in Prostate Cancer. Cancer Res Am Assoc Cancer Res. 2000;60:944–9.

CAS  Google Scholar 

Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38:652–8.

CAS  Article  Google Scholar 

Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline Mutations in HOXB13 and Prostate-Cancer Risk [Internet]. https://doi.org/10.1056/NEJMoa1110000. Massachusetts Medical Society; 2012 [cited 2021 Jul 1]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1110000.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375:443–53.

CAS  Article  Google Scholar 

Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol. 2020;77:24–35.

CAS  Article  Google Scholar 

Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79:880–95.

CAS  Article  Google Scholar 

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373:1697–708.

CAS  Article  Google Scholar 

Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39:631–7.

CAS  Article  Google Scholar 

Benafif S, Kote-Jarai Z, Eeles RA. A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). Cancer Epidemiol Biomarkers Prev.  2018;27:845–57.

Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–60.

CAS  Article  Google Scholar 

McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor Genome Biology. 2016;17:122.

PubMed  Google Scholar 

Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–43.

CAS  Article  Google Scholar 

Ameur A, Dahlberg J, Olason P, Vezzi F, Karlsson R, Martin M, et al. SweGen: a whole-genome data resource of genetic variability in a cross-section of the Swedish population. Eur J Hum Genet. 2017;25:1253–60.

CAS  Article  Google Scholar 

Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores. Genome Med. 2021;13:31.

CAS  Article  Google Scholar 

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928–36.

CAS  Article  Google Scholar 

Bailey JA, Gu Z, Clark RA, Reinert K, Samonte RV, Schwartz S, et al. Recent Segmental Duplications in the Human Genome. 297: Science. American Association for the Advancement of Science; 2002. pp. 1003–7.

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw Natl Compr Cancer Netw. 2019;17:479–505.

CAS  Article  Google Scholar 

Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48:D845–55.

PubMed  Google Scholar 

Yu G, Wang L-G, Han Y, He Q-Y clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. OMICS: A Journal of Integrative Biology. Mary Ann Liebert, Inc., publishers; 2012;16:284–7.

Semplicini C, Vissing J, Dahlqvist JR, Stojkovic T, Bello L, Witting N, et al. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology. 84: Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2015. pp. 1772–81.

Agnarelli A, Chevassut T, Mancini EJ. IRF4 in multiple myeloma—Biology, disease and therapeutic target. Leuk Res. 2018;72:52–8.

CAS  Article  Google Scholar 

Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al. TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. Cancer Res American Association for Cancer Research. 2006;66:3396–400.

CAS  Google Scholar 

Qin J, Lee H-J, Wu S-P, Lin S-C, Lanz RB, Creighton CJ, et al. Androgen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest American Society for Clinical Investigation. 2014;124:5013–26.

CAS  Article  Google Scholar 

Olsson M, Gustafsson O, Skogastierna C, Tolf A, Rietz BD, Morfin R, et al. Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma. Prostate. 2007;67:1439–46.

CAS  Article  Google Scholar 

Jakobsson J, Karypidis H, Johansson J-E, Roh H-K, Rane A, Ekström L. A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians. Pharmacogenomics J. 2004;4:245–50.

CAS  Article  Google Scholar 

Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, et al. Peroxisome Proliferator-activated Receptor α Is an Androgen-responsive Gene in Human Prostate and Is Highly Expressed in Prostatic Adenocarcinoma. Clin Cancer Res American Association for Cancer Research. 2000;6:3241–8.

CAS  Google Scholar 

Andreotti G, Koutros S, Berndt SI, Hughes Barry K, Hou L, Hoppin JA, et al. The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk. J Cancer Epidemiol Hindawi. 2012;2012:e358076.

Google Scholar 

Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, et al. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. Eur Urol. 2021;80:71–81.

CAS  Article  Google Scholar 

Seethy A, Pethusamy K, Chattopadhyay I, Sah R, Chopra A, Dhar R, et al. TETology: Epigenetic Mastermind in Action. Appl Biochem Biotechnol. 2021;193:1701–26.

CAS  Article  Google Scholar 

Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, et al. TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene. 2017;36:2172–83.

CAS  Article  Google Scholar 

Geybels MS, Zhao S, Wong C-J, Bibikova M, Klotzle B, Wu M, et al. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue. Prostate. 2015;75:1941–50.

CAS  Article  Google Scholar 

Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.

CAS  Article  Google Scholar 

Yin B, Zhang M, Zeng Y, Li Y, Zhang C, Getzenberg RH, et al. Downregulation of cytokeratin 18 is associated with paclitaxel–resistance and tumor aggressiveness in prostate cancer. Int J Oncol. 2016;48:1730–6.

CAS  Article  Google Scholar